Navigation Links
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Date:3/11/2011

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.  

Following preliminary review of the data, no new or unexpected treatment-related safety concerns have emerged during the DEFEND-1 study. Study investigators and regulatory agencies have been notified of the DEFEND-1 study outcome.

GSK will continue to explore additional dosing regimens to inform decisions about the future clinical development programme for otelixizumab.  New recruitment and dosing in the DEFEND-2 study, the ongoing confirmatory Phase 3 study with a design similar to DEFEND-1, has been suspended pending review of the DEFEND-1 results.

"While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx. "Our immunotherapy candidates represent some of the latest scientific advances in harnessing the immune system for therapeutic benefit, including TRX518 which is a showpiece of our pipeline as an immunotherapy to treat cancer."

"Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward," said Jackie Parkin, Medicines Development Leader, GlaxoSmithKline.

Tolerx Pipeline

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
3. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
4. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
5. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
8. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
9. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. GlaxoSmithKline Wins Environmental Stewardship Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... issued the following statement today in support of President ... "As the global leader in rapid diagnostics ... a national strategy to address the serious threat of ... with the Administration on initiatives to promote the development ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- , ... Huntington,s Disease and Others-- , , RESEARCH TRIANGLE ... clinical stage company developing and commercializing innovative treatments for ... that it has obtained the rights to develop and ...
... June 15 Vitamin D deficiency was found to be ... the results of a recent study conducted at ... these results, CTCA researchers determined that screening for vitamin D ... all people with cancer. , , (Logo: ...
Cached Medicine Technology:CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 2CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 3Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients 2
(Date:9/20/2014)... September 20, 2014 The print ... today’s edition of the Calgary Herald, with a ... readership of 270,000. The digital component is distributed ... across a network of top news sites and ... the campaign, visit http://www.worklifebalanceinfo.ca . , The ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... festival season is coming soon. The high-end fashion designer BellasDress ... dresses . A lot of sophisticated women like its new ... promotion for its high quality clothes. Now, each of its ... to 71 percent off. , The company’s cocktail dress ... in many fashionable colors. Mary, the company’s sales manager, believes ...
(Date:9/20/2014)... TX (PRWEB) September 20, 2014 ... Forecast and Market Analysis to 2023?. The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... Dynatronics,Corporation (Nasdaq: DYNT ) today announced ... Mike Draper and Tom Draper, both of Wichita, ... as direct sales representatives. Dynatronics now offers ... our direct distribution presence is helping improve,profit margins ...
... BIRMINGHAM, Ala., Oct. 10 Aeon Bioscience,Inc. ... of its key,collaborators, Brookwood Pharmaceuticals, Inc. by ... to develop improvements in drug-eluting stent,technology for ... Bioscience was formed as a collaborative enterprise ...
... Achievement,and Innovation in Patient-Centered Approaches to Care, ... Hospital of,Warrenton, VA has been formally recognized ... Hospital." This designation,recognizes Fauquier,s achievement and innovation ... prioritizes patient comfort, dignity, empowerment,and well-being, while ...
... eHI Blueprint Offers Multi-Stakeholder Consensus on a Shared Vision, ... ... Through Information Technology, WASHINGTON, Oct. 10 Today the ... Common Action, which represents multi-stakeholder,consensus on a shared vision and ...
... A report to be published in an upcoming issue ... urgent attention to the politically sensitive issue of border control, ... the face of a catastrophic flu pandemic . The ... a strain of avian influenza A (HN51) in Northern Sumatra: ...
... Oct. 10 CBIZ, Inc. (NYSE: CBZ ) has,scheduled ... a.m.,(ET) to discuss the Company,s financial results for the third-quarter ... the,market opens the morning of October 25, 2007. At that ... Company,s web site at http://www.cbiz.com . The call ...
Cached Medicine News:Health News:Dynatronics Adds Three Additional Direct Sales Reps 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 3Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 4Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 2Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 2Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 4Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:CBIZ Webcasts Third-Quarter 2007 Conference Call 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: